文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

印度、菲律宾、俄罗斯和南非耐多药与广泛耐药结核未来负担的数学建模预测

Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study.
PubMed 文献 · Lancet Infect Dis · 2017-05-09

研究用隔室模型结合耐药调查与WHO结核报告数据,预测印度、菲律宾、俄罗斯和南非2000至2040年耐多药(MDR)与广泛耐药(XDR)结核发病趋势。模型预测四国结核incident病例中MDR比例及MDR中XDR比例均上升,获得性耐药仅解释不足30%的MDR发病,需在改善获得性耐药之外加强控制措施。

要点

  • 四国2040年MDR占incident结核比例预测均上升,俄罗斯最高达32·5%。
  • 2040年XDR占incident MDR比例四国均约8·5%–9·0%。
  • 获得性耐药仅解释不足30%的MDR发病,需额外控制措施。

核心结论

  • 模型预测四国MDR与XDR结核均增加,尽管获得性耐药有所改善,仍需额外控制措施阻断传播。

研究设计与样本

  • 隔室模型校准耐药调查与WHO结核报告数据,预测印度、菲律宾、俄罗斯和南非2000–2040年MDR与XDR结核趋势,假设耐药无适应性代价。

主要发现

  • 2040年incident结核中MDR比例:印度12·4%(95%预测区间9·4–16·2)、菲律宾8·9%(4·5–11·7)、俄罗斯32·5%(27·0–35·8)、南非5·7%(3·0–7·6)。
  • 2040年incident MDR中XDR比例:印度8·9%(5·1–12·9)、菲律宾9·0%(4·0–14·7)、俄罗斯9·0%(4·8–14·2)、南非8·5%(2·5–14·7)。
  • 2000–2040年获得性耐药引起的incident MDR不足30%;XDR中由获得性耐药引起者从2000年80%降至2040年不足50%。

临床怎么用

  • 对高MDR负担国家,除改善获得性耐药外需加强传播控制以遏制MDR与XDR结核上升。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are emerging worldwide. The Green Light Committee initiative supported programmatic management of drug-resistant tuberculosis in 90 countries. We used estimates from the Preserving Effective TB Treatment Study to predict MDR and XDR tuberculosis trends in four countries with a high burden of MDR tuberculosis: India, the Philippines, Russia, and South Africa. METHODS: We calibrated a compartmental model to data from drug resistance surveys and WHO tuberculosis reports to forecast estimates of incident MDR and XDR tuberculosis and the percentage of incident MDR and XDR tuberculosis caused by acquired drug resistance, assuming no fitness cost of resistance from 2000 to 2040 in India, the Philippines, Russia, and South Africa. FINDINGS: The model forecasted the percentage of MDR tuberculosis among incident cases of tuberculosis to increase, reaching 12·4% (95% prediction interval 9·4-16·2) in India, 8·9% (4·5-11·7) in the Philippines, 32·5% (27·0-35·8) in Russia, and 5·7% (3·0-7·6) in South Africa in 2040. It also predicted the percentage of XDR tuberculosis among incident MDR tuberculosis to increase, reaching 8·9% (95% prediction interval 5·1-12·9) in India, 9·0% (4·0-14·7) in the Philippines, 9·0% (4·8-14·2) in Russia, and 8·5% (2·5-14·7) in South Africa in 2040. Acquired drug resistance would cause less than 30% of incident MDR tuberculosis during 2000-40. Acquired drug resistance caused 80% of incident XDR tuberculosis in 2000, but this estimate would decrease to less than 50% by 2040. INTERPRETATION: MDR and XDR tuberculosis were forecast to increase in all four countries despite improvements in acquired drug resistance shown by the Green Light Committee-supported programmatic management of drug-resistant tuberculosis. Additional control efforts beyond improving acquired drug resistance rates are needed to stop the spread of MDR and XDR tuberculosis in countries with a high burden of MDR tuberculosis. FUNDING: US Agency for International Development and US Centers for Disease Control and Prevention, Division of Tuberculosis Elimination.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sharma A, Hill A, Kurbatova E, et al. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study. Lancet Infect Dis. 2017. PMID: 28499828. doi:10.1016/S1473-3099(17)30247-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。